2024 - 2032 年核医市场机会、成长动力、产业趋势分析与预测

Nuclear Medicine Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年11月11日 | 出版商:

Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3个工作天内

价格

简介目录

全球核子医学市场将于2023 年达到136 亿美元，并有望强劲成长，预计2024 年至2032 年复合年增长率为16.3%。强劲需求诊断技术与放射性药物的持续创新。随着医疗保健提供者和患者越来越优先考虑先进的诊断和治疗选择，这些因素对市场扩张做出了重大贡献。

各国政府和研究组织广泛投资于核子医学研究和开发。这些投资旨在加强医疗基础设施、扩大诊断范围并改善公共卫生结果。已开发国家已启动国家倡议，为尖端成像技术和放射性药物基础设施提供资金，提高诊断能力并支持核医解决方案的采用。

从细分市场来看，市场分为诊断和治疗，诊断细分市场到2023 年将产生94 亿美元的收入。地获得先进的核子成像工具。这些地区慢性病发病率的上升进一步推动了对核子诊断的需求。核子造影方法，特别是心肌灌注造影（MPI），透过评估血流、识别心臟病和评估心臟功能，在心臟病学中发挥至关重要的作用。随着生活方式的改变和人口老化导致全球心臟病盛行率上升，透过核诊断进行心臟影像的需求不断增加。

市场范围
开始年份	2023年
预测年份	2024-2032
起始值	136 亿美元
预测值	547 亿美元
复合年增长率	16.3%

根据最终用途，核医市场涵盖医院、诊断中心、研究机构和其他设施。医院是 2023 年的主导部分，预计到 2032 年将达到 333 亿美元。医院也越来越多地采用混合成像系统，例如 PET/CT、SPECT/CT 和 PET/MRI，这些系统透过整合解剖和功能性影像来提高诊断精度。这些复杂的系统通常安装在资源丰富的医院环境中，导致患者数量增加。

2023 年，北美核医收入达70 亿美元，预计到2032 年复合年增长率为15.6%。成像系统。北美设备齐全的医院、专科诊所和诊断中心非常适合整合先进的核子医学解决方案。此外，人口老化越来越容易患慢性和与年龄相关的疾病，包括阿兹海默症和各种癌症，这进一步扩大了对核诊断用于早期检测和个人化治疗策略的需求。

产业生态系统分析
产业影响力
- 成长动力
  - 慢性病盛行率不断上升
  - 核子医学技术不断进步
  - 医疗保健支出增加
  - 有利的政府倡议
- 产业陷阱与挑战
  - 放射治疗费用高
  - 放射性药物的半衰期短
成长潜力分析
监管环境
报销场景
技术景观
- 核心技术
- 邻近技术
未来市场趋势
管道分析
波特的分析
PESTEL分析
差距分析

第 4 章：竞争格局

介绍
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

主要趋势
诊断
- 单光子发射电脑断层扫描 (SPECT) 同位素
  - TC-99m
  - I-123
  - GA-67
  - TL-201
  - 其他 SPECT 同位素
- 正子断层扫描 (PET) 同位素
  - F-18
  - RB-82
  - 其他 PET 同位素
疗法
- 贝塔发射体
  - I-131
  - 卢-177
  - Y-90
  - SM-153
  - 重新186
  - 其他β发射体
- 近距离放射治疗同位素
  - 铱192
  - 碘125
  - 铯131
  - 钯103
  - 其他近距离放射治疗同位素
- 阿尔法发射器
  - RA-223
  - 其他阿尔法发射体

第 6 章：市场估计与预测：按应用分类，2021 - 2032

主要趋势
神经病学
心臟病学
肿瘤学
甲状腺
肺部
其他应用

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

主要趋势
医院
诊断中心
科学研究机构
其他最终用户

第 8 章：市场估计与预测：按地区划分，2021 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋

第 9 章：公司简介

Actinium Pharmaceuticals
Boston Scientific
Bracco
Cardinal Health
Curium Pharma
GE Healthcare
Jubilant Pharma
Lantheus
Novartis
RadioMedix
RLS Radiopharmacies
Siemens Healthineers
Sirtex
Sun Pharma
Theragenics

简介目录

Product Code: 12229

The Global Nuclear Medicine Market reached USD 13.6 billion in 2023 and is poised for robust growth, with a projected CAGR of 16.3% from 2024 to 2032. Key growth drivers include the rising incidence of cancer and cardiovascular diseases, a strong demand for non-invasive diagnostic techniques, and continuous innovation in radiopharmaceuticals. These factors contribute significantly to market expansion as healthcare providers and patients increasingly prioritize advanced diagnostic and therapeutic options.

Governments and research organizations invest extensively in nuclear medicine research and development. These investments aim to enhance healthcare infrastructure, broaden diagnostic access, and improve public health outcomes. Developed countries have launched national initiatives that provide funding for cutting-edge imaging technologies and radiopharmacy infrastructure, advancing diagnostic capabilities and supporting the adoption of nuclear medicine solutions.

Segment-wise, the market is divided into diagnostics and therapeutics, with the diagnostics segment generating USD 9.4 billion in revenue in 2023. Emerging markets are experiencing rising healthcare investments and improved infrastructure, enabling greater access to advanced nuclear imaging tools. Increased rates of chronic diseases in these regions further propel demand for nuclear diagnostics. Nuclear imaging methods, especially myocardial perfusion imaging (MPI), play a crucial role in cardiology by evaluating blood flow, identifying heart diseases, and assessing cardiac function. As lifestyle changes and an aging population drive up heart disease prevalence globally, the need for cardiac imaging through nuclear diagnostics continues to rise.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$13.6 Billion
Forecast Value	$54.7 Billion
CAGR	16.3%

Based on end-use, the nuclear medicine market spans hospitals, diagnostic centers, research institutes, and other facilities. Hospitals were the dominant segment in 2023 and are projected to reach USD 33.3 billion by 2032. Investments in advanced imaging technologies and the employment of specialized nuclear medicine professionals enable hospitals to offer a broad range of nuclear medicine applications, from diagnostics to theranostics. Hospitals are also increasingly adopting hybrid imaging systems, such as PET/CT, SPECT/CT, and PET/MRI, which enhance diagnostic precision by integrating anatomical and functional imaging. These sophisticated systems are typically housed in well-resourced hospital environments, leading to higher patient volumes.

North America accounted for USD 7 billion in nuclear medicine revenue in 2023, with a forecasted CAGR of 15.6% through 2032. The region's advanced healthcare infrastructure facilitates the adoption of nuclear imaging technologies, especially hybrid imaging systems like PET/CT and SPECT/CT. North America's well-equipped hospitals, specialty clinics, and diagnostic centers are well-suited to integrating advanced nuclear medicine solutions. Additionally, an aging population increasingly susceptible to chronic and age-related conditions, including Alzheimer's and various cancers, further amplifies the demand for nuclear diagnostics for early detection and personalized treatment strategies.

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing prevalence of chronic diseases
  - 3.2.1.2 Rising technological advancements in nuclear medicine
  - 3.2.1.3 Rise in healthcare expenditure
  - 3.2.1.4 Favorable government initiatives
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of radiotherapy
  - 3.2.2.2 Short half-life of radiopharmaceuticals
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Reimbursement scenario
3.6 Technology landscape
- 3.6.1 Core technologies
- 3.6.2 Adjacent technologies
3.7 Future market trends
3.8 Pipeline analysis
3.9 Porter's analysis
3.10 PESTEL analysis
3.11 Gap analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Diagnostics
- 5.2.1 Single Photon Emission Computed Tomography (SPECT) isotopes
  - 5.2.1.1 TC-99m
  - 5.2.1.2 I-123
  - 5.2.1.3 GA-67
  - 5.2.1.4 TL-201
  - 5.2.1.5 Other SPECT isotopes
- 5.2.2 Positron Emission Tomography (PET) isotopes
  - 5.2.2.1 F-18
  - 5.2.2.2 RB-82
  - 5.2.2.3 Other PET isotopes
5.3 Therapeutics
- 5.3.1 Beta emitters
  - 5.3.1.1 I-131
  - 5.3.1.2 Lu-177
  - 5.3.1.3 Y-90
  - 5.3.1.4 SM-153
  - 5.3.1.5 Re-186
  - 5.3.1.6 Other beta emitters
- 5.3.2 Brachytherapy isotopes
  - 5.3.2.1 Iridium-192
  - 5.3.2.2 Iodine-125
  - 5.3.2.3 Cesium-131
  - 5.3.2.4 Palladium-103
  - 5.3.2.5 Other brachytherapy isotopes
- 5.3.3 Alpha emitters
  - 5.3.3.1 RA-223
  - 5.3.3.2 Other alpha emitters

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Neurology
6.3 Cardiology
6.4 Oncology
6.5 Thyroid
6.6 Pulmonary
6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Diagnostic centres
7.4 Research institutes
7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 1.1.1 Argentina
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE